CYW 628
Alternative Names: CYW-628; CYWC-628Latest Information Update: 24 May 2024
At a glance
- Originator FibroBiologics
- Class Fibroblast cell therapies; Foot disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic foot ulcer
Most Recent Events
- 22 Apr 2024 Preclinical trials in Diabetic foot ulcers in USA (Parenteral) (Fibrobiologics pipeline, April 2024)
- 22 Apr 2024 Fibrobiologics intends to submit an IND application for phase I/II trial to the US FDA for Diabetics foot ulcer as early as 2024 (Fibrobiologics pipeline, April 2024)
- 16 Mar 2023 Fibrobiologics has patents pending for the Therapeutic use of fibroblasts for use in wound healing in the US, Japan, Australia, Europe and the World